Relay Therapeutics (RLAY) Q1 2026 earnings review
Clinical Wins and Heavy Dilution Extend Runway to 2029
Relay Therapeutics reported a stable net loss of $73.3M while making significant clinical strides, highlighted by an FDA Breakthrough Therapy designation for its lead asset, zovegalisib. However, the company is funding this progress through aggressive shareholder dilution, tapping its 'at-the-market' (ATM) facility for $137.1M in Q1 and another $22.1M in April. While operating expenses are structurally lower following last year's restructuring, the timeline for the critical Phase 3 frontline breast cancer trial has been pushed to early 2027, requiring substantial investor patience.
🐂 Bull Case
FDA Breakthrough Therapy designation in 2L breast cancer and consistent 11.1-month median PFS data significantly de-risk the lead clinical program.
Recent ATM equity offerings have bolstered the balance sheet to $642M+, providing a clear financial runway into 2029 without immediate financing overhangs.
🐻 Bear Case
The $159M raised via the ATM facility so far in 2026 materially increases the share count, diluting existing shareholders before pivotal Phase 3 data is generated.
The Phase 3 trial for frontline (1L) breast cancer is not expected to initiate until early 2027, leaving a prolonged gap before next-stage commercial validation.
⚖️ Verdict: ⚪
Neutral. The underlying clinical execution and partnership strategy with Pfizer are sound. However, the heavy reliance on ATM equity issuance and the long wait for the 1L Phase 3 trial initiation neutralize the near-term upside.
Key Themes
Zovegalisib Secures Breakthrough Therapy Designation
The FDA granted Breakthrough Therapy designation for zovegalisib in combination with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer. This was backed by robust Phase 1/2 ReDiscover data showing an 11.1-month median progression-free survival (PFS) in heavily pre-treated patients, reinforcing the asset's clinical viability.
Strategic Pfizer Alliance for Frontline Treatment
Relay selected the zovegalisib plus atirmociclib triplet regimen for 1L breast cancer, supported by a 44% objective response rate in CDK4/6-experienced patients. Crucially, they secured a clinical supply agreement with Pfizer for atirmociclib, validating the combination strategy while allowing Relay to retain full global rights to zovegalisib.
Heavy Shareholder Dilution
To extend its cash runway, the company utilized its ATM facility aggressively, generating $137.1M in net proceeds in Q1 2026 and an additional $22.1M in April. The basic and diluted weighted average shares increased from 169.2M in 25Q1 to 179.8M in 26Q1, actively diluting current equity holders.
Operating Expense Reductions Hold Steady
Management's 2024/2025 strategic restructuring continues to bear fruit. Total operating expenses decelerated to $81.6M in 26Q1 from $92.5M a year ago. G&A expenses saw a particularly sharp 41% YoY decline (down to $11.0M) due to lower stock compensation and completion of prior licensing transaction costs.
Prolonged Pipeline Timelines
Despite strong data, the Phase 3 1L trial in endocrine-sensitive breast cancer patients is not expected to initiate until 'early 2027.' This represents a significant gap in time before the pivotal trial even begins, exposing the company to shifting standards of care and market fatigue.
Vascular Anomalies Reaching Catalyst Window
A secondary value driver is emerging: initial clinical results for zovegalisib in PIK3CA-driven vascular anomalies will be presented in mid-May at the ISSVA World Congress. With an estimated 170,000 addressable patients in the U.S., positive data here could unlock a massive non-oncology market opportunity.
Other KPIs
Stable. The net loss narrowed slightly compared to -$77.1M in 25Q1. This stability reflects a disciplined R&D approach following previous portfolio trimmings, offset by the expected ramp in the Phase 3 ReDiscover-2 trial costs.
Decelerating YoY but slightly accelerating sequentially. Down from $73.8M in 25Q1 due to the 80% reduction in early research run rate spend implemented previously, though costs are creeping back up sequentially (from $68.3M in 25Q3) as late-stage trials expand.
Decelerating. Revenue fell from $7.7M in 25Q1. All revenue is currently derived from the Elevar Therapeutics license agreement and remains immaterial to the core investment thesis of this clinical-stage biotech.
Guidance
Stable. Management explicitly reiterated that current cash of $642.1M will fund operations and capital expenditures into 2029. This is a direct result of the $159M in recent ATM equity sales extending the timeline.
A critical timeline guidance indicating when the frontline breast cancer triplet combination will formally enter pivotal testing, pending regulatory feedback.
Key Questions
1L Phase 3 Timeline Rationale
What specific regulatory feedback or manufacturing scale-up factors are gating the initiation of the Phase 3 1L trial until early 2027, rather than advancing it in 2026?
Pfizer Agreement Economics
Are there any milestone payments, cost-sharing mechanics, or downstream royalty obligations baked into the clinical supply agreement with Pfizer for atirmociclib?
Future Funding Strategy
With cash runway extended to 2029 via the ATM facility, does management intend to pause further equity dilution in 2026, or will the ATM remain actively utilized on price spikes?